ReviewAnnals of intensive care2025
Biomarkers to guide sepsis management.
Review in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of blood copeptin level for the prediction of mortality of adult patients with sepsis: a meta-analysis.Frontiers in medicine · 2025Pooled it
- Sepsis Recognition and Management Gaps in Hospitals: A Post Hoc Analysis of a Subset of Data from the European Sepsis Care Survey.Infectious diseases and therapy · 2026Article
- Heparin-Binding Protein and Transplant-Associated Inflammation: Emerging Roles in Infection, Ischemia-Reperfusion Injury, and Allograft Dysfunction.Journal of clinical medicine · 2026Review
- Article
- Diagnostic accuracy of PCT, IL-6, and MR-ProADM for early identification of sepsis in the emergency department.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Observational
- Precision medicine in sepsis: lessons from the TIGRIS trial and the reawakening of targeted therapy.Journal of anesthesia, analgesia and critical care · 2026Review
- Article
- Association between shock‑lactate index and 28-day mortality in patients with sepsis-associated AKI: a MIMIC-IV database analysis.BMC infectious diseases · 2026Observational
- Development and validation of a prediction model for infection in chronic nonhealing wounds: a two-center retrospective study with external validation.Frontiers in public health · 2026Article
- Recent advances in early screening and diagnosis of sepsis: a narrative review.Frontiers in cellular and infection microbiology · 2026Review
- Inflammation-driven immune reprogramming in sepsis: from cytokine storm to immunoparalysis.Frontiers in immunology · 2026Review
- How do immunometabolites shape bacterial infections?PLoS biology · 2026Article
- Multi-omic and computational approaches for biomarker discovery and clinical translation in pediatric sepsis.Frontiers in pharmacology · 2026Review
- Non-Sexually Transmitted Infection (STI)-Related Pelvic Inflammatory Disease (PID).Microorganisms · 2025Review
- Cell-free DNA in sepsis: from molecular insights to clinical management.Military Medical Research · 2025Review
- Identification and validation of an endotoxin tolerance-based prognostic model with therapeutic insights in sepsis.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis remains a major cause of morbidity and mortality. Precision therapeutics are now regarded as a novel prospective to improve outcome. This approach relies on biomarkers to identify a pathway of pathogenesis which prevails and directs the best available therapeutic option to modulate this pathway. This review provides the most recent findings on biomarkers for bacterial or viral sepsis. These biomarkers provide guidance for prompt diagnosis and management tailored to specific needs. MAIN BODY: Keywords relative to sepsis management (early recognition, antibiotic administration, selection of fluids, vasopressors and immunotherapy) were searched across PubMed database. Published evidence the last five years exists for heparin-binding protein (HBP), monocyte distribution width (MDW), interleukin-10 (IL-10), presepsin, procalcitonin and C-reactive protein (CRP) for early sepsis diagnosis; procalcitonin is the most well-studied biomarker for antibiotic guidance. Endothelial and cardiac biomarkers have been explored as tools to tailor circulatory support in sepsis, including fluid therapy, and the targeted use of vasopressors for vascular tone optimization.
conclusionThis review explored how biomarkers can optimize immunomodulatory therapies, guide vasopressor initiation, inform antibiotic stewardship, and aid in fluid resuscitation decisions, ultimately improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.